Medical device company Creo Medical Group plc (AIM: CREO) on Wednesday announced the commencement of the first robotic-guided microwave ablation procedures for cancerous lung tissue at a leading UK hospital.
This follows an amendment to the company's collaboration with Intuitive, announced in July 2024, which integrates Creo's MicroBlate Flex ablation device with Intuitive's Ion Endoluminal System.
The hospital is the second UK site to perform such procedures, joining Royal Brompton Hospital, which began similar operations as part of an ongoing clinical study led by Professor Shah. The procedures are part of the Pioneer Programme, which will continue to gather clinical evidence throughout 2025 before transitioning to a commercial phase. Creo expects the number of procedures to increase within the current year.
Creo Medical specialises in developing minimally invasive electrosurgical devices for cancer treatment, including its CROMA system powered by Kamaptive technology. This advanced energy platform enables precise tissue manipulation for resection, dissection, coagulation and ablation, offering increased flexibility, precision and control in surgical procedures.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval